Document:

exv10w27

Exhibit 10.27

     Agreement dated as of the day of April 2010 by and between CytoCore, Inc., a Delaware
corporation with offices located at 414 N. Orieans Street, Chicago, II 60610 (the Company) and Dr.
Mauro Scimia, located in Via dei Faggi 2 -00062 Bracciano (Rome, Italy)

(“Consultant”)

               1.) Consultant shall devote a substantial amount of his time
and
effort to develop a distribution system for the Company’s products in Europe. Consultant
shall identify reputable and experienced distributors and other health care providers such as
laboratories and medical groups and upon authorization by the Company negotiate the terms of
distribution and sales agreements, subject to the Company’s prior approval and execution of such
agreements. The Distributors shall be assigned exclusive Areas so that the major markets in Europe
will be adequately served. The Company shall determine the Areas, transfer pricing and minimum
quantities acceptable to the Company to enter into any distribution and sales agreements,. Upon
execution of the distribution and sales agreements, Consultant shall work with the distributors and
health care providers on the Company’s behalf to implement said agreements.

               2.) Consultant shall provide a sales plan and projections by country, distributor and health
care providers on a monthly basis and shall report monthly on the results of such plan to the CEO
of the Company and its Director of International Sales.

               3.) Consultant shall receive a commission of 10% of gross
revenues received by the Company from the distributors for Company products sold to them. The
Company may terminate any or all of the distributors upon the Company’s determination that such
distributor(s) are not producing sufficient sales, poor payment history with the. Gross revenue
shall be determined on the basis of F.O.B., point of manufacture. In addition, gross revenue shall
be reduced by refunds, returns or allowances and bad debts.

               4.) (a) The commission due to Consultant on the sale of
Company products to the distributors or labs or other health providers shall be paid to Consultant
during the term of this Agreement including any extensions thereto. Upon the expiration of this
Agreement or extension thereto or earlier termination of this Agreement, Consultant shall receive a
commission of 7% of gross revenue received from the distributors introduced by him to the Company
during the 12 months thereafter, 5% of gross revenues during the following 12 months and 1% during
the third year after expiration or earlier termination.

 

 

               (b) Consultant shall receive a monthly advance fee (Draw) of
2,000 Euros/month to be offset against future commissions earned by Consultant.

               (c) 35% of the commissions due Consultant shall be paid
upon the sale and delivery and invoicing of inventory to distributors or health providers, reduced
by Draw previously paid by the Company to Consultant; the balance shall be paid with 10 days after
payment by the distributor to the Company has cleared or letter of credit has been received by the
Company.

               (d) The Company will provide Consultant with the basis upon
which the Company has determined commissions to be due to Consultant. Consultant
may request an audit of such calculation. The Company shall perform such audit, but
Consultant will be charged for such expense unless the audit determines that the
commission paid to the Consultant is less than 95% of the correct commission amount.

               (e) Payment of commissions shall be paid in U.S. Dollars.
Conversion of U.S. Dollars into Euros will be responsibility of the Consultant.

               (f) Consultant is authorized to incur reasonable, ordinary and
necessary business expenses in the performance of his duties, except that any expense of $200.00 or
higher shall require the prior approval of Director of International Sales and for expenses over
$500 approval by the CEO of the Company. Approved consultant expenses will be reimbursed by bank
wire by dollars after translated into Euros within 14 calendar days of submission.

Consultant shall be eligible to receive the following grants of common stock based on
performance:

     (a) 100,000 shares of common stock of the Company should sales generated by
Consultant’s customers equal or exceed U.S. $1,000,000 during the first 12 months of
the
contract.

     (b) 200,000 shares of common stock of the Company should sales by Consultants’
Customers equal or exceed U.S. $2,500,000 during the first 12 months of the contract.

     (c) 100,000 shares of common stock of the Company should sales to Consultant’s
customers equal or exceed U.S. $4,000,000 during the second year of the contract.

     (d) 200,000 shares of common stock of the Company should sales to Ocana Distributors
equal or exceed U.S. $6,000,000 during the second year of the contract

Consultant may receive other bonus upon the company’s discretion.

               5.) The term of this Agreement shall commence on the date a fully executed Agreement is
received by Consultant and shall continue in full force and effect for a

 

 

probationary period of 6 months during which any party may terminate. All amounts outstanding
will be paid to the consultant. Notwithstanding the foregoing, the Company may continue this
Agreement without continuing to pay a Draw if, in the Company’s sole discretion, it determines that
progress in implementing the distribution system is not proceeding as rapidly as anticipated,
Consultant will provide a 3 month notice of termination, during
which he will ensure a smooth and
professional termination, including the transition of assignments and contacts to persons or other
consultants designated by the company. Company will provide a 9 month notice of termination to the
consultant. In the event the company decides not to use the Consultant’s services during the 9 month
period, consultant will be paid for the full 9 months. If consultant leaves voluntarily before the
9 month period expires, all consultancy fees will terminate.

               6.) Consultant is providing services to the Company as an
independent contractor and shall not be deemed to be an employee of the Company for any purpose.

          IN WITNESS WHEREOF, the parties hereto have set their hands this 14 day of April 2010.

	 	 	 	 	 
	 	CYTOCORE, INC.

 	 
	 	By:  	/s/ Robert F. McCullough
 	 
	 	 	 	 
	 	 	 	 
	 
	 	 	 
	 	/s/ Dr. Mauro Scimia
 	 
	 	Dr. Mauro Scimiaexv10w28

Exhibit 10.28

Cytocore/Amsino Distribution Service Agreement

Basic Terms

Revised April 15, 2009

	1.	 	Overview- Cytocore offers specialty diagnostic and treatment products to the healthcare
market. Amsino International, Inc. offers sales channel and distribution services to that
market.
	 
	2.	 	Cytocore will designate Amsino as the exclusive worldwide sales channel and
distribution
partner.
	 
	3.	 	Sales Channel Services will include but not limited to:

	 	a.	 	Introduction of Cytocore management to selected end user distributors such as:

	 	i.	 	PSS
	 
	 	ii.	 	McKesson
	 
	 	iii.	 	Henry Schein
	 
	 	iv.	 	Cardinal
	 
	 	v.	 	Labsco
	 
	 	vi.	 	Infolab
	 
	 	vii.	 	Cooper Surgical
	 
	 	viii.	 	Nipro (Latin America Market)

	 	b.	 	Introduction of Cytocore to distributor associations such as:

	 	i.	 	IMCO
	 
	 	ii.	 	NDC (Abco, CIDA, Starline)

	4.	 	Distribution services will include but not limited to:

	 	a.	 	China to US logistics (Amsino warehouse or customer)
	 
	 	b.	 	Warehousing and inventory management
	 
	 	c.	 	Order management (Purchase order to delivery to distributor customer)
	 
	 	d.	 	Customer Service

	5.	 	Proposed Process Flow (Subject to revision prior to formal
contract)

	 	a.	 	Amsino produces products per Cytocore forecast
	 
	 	b.	 	Cytocore purchases product from Amsino manufacturing facility in China at a
FOB China
price.
	 
	 	c.	 	Cytocore to retain title to the product until invoiced to distributor
customer (i.e. PSS,
Henry Schein)
	 
	 	d.	 	Amsino China and Pomona office manages logistics required to bring product
from
China to Pomona warehouse.
	 
	 	e.	 	Cytocore to pay freight from China to Amsino Pomona warehouse.
	 
	 	f.	 	Amsino to warehouse the product with a “3PL” scenario.
	 
	 	g.	 	Product is owned by Cytocore. Amsino will not take title to the product.
	 
	 	h.	 	Additional Services Provided by Amsino

	 	i.	 	Receive and upload product from containers

 

 

	 	ii.	 	Palletize and wrap
	 
	 	iii.	 	Put away into dedicated warehouse locations
	 
	 	iv.	 	Receive preservative
	 
	 	v.	 	Assemble kits (place SoftPap and preservative product in one carton)
	 
	 	vi.	 	Inventory kits
	 
	 	vii.	 	Receive orders and shipping instructions from Cytocore
	 
	 	viii.	 	Pick, Pack, and Ship product to distributor customer
	 
	 	ix.	 	Invoice the customer

	 	i.	 	Customer remits payment to Cytocore (bank lock box)
	 
	 	j.	 	Cytocore to pay freight to distributor customer
	 
	 	k.	 	Cytocore to establish sell prices.

	6.	 	Amsino Compensation

	 	a.	 	Amsino will be paid, by Cytocore, $1.00 (per unit sold) above direct expenses
	 
	 	b.	 	Direct expenses include

	 	i.	 	Pallets and wrapping material
	 
	 	ii.	 	Cartons and related material for kit assembly
	 
	 	iii.	 	Ocean freight and fees
	 
	 	iv.	 	Freight to customer

	7.	 	Additional Consideration

	 	a.	 	Amsino to provide weekly sales information to Cytocore
	 
	 	b.	 	Amsino to provide weekly inventory information to Cytocore
	 
	 	c.	 	Cytocore responsible for marketing program expenses.

	8.	 	Open Issues for Discussion
	 
	9.	 	This term sheet does not represent a formal contract. All terms and conditions are subject to
change upon development of final agreement.
	 
	10.	 	Amsino will maintain Cytocore’s receivables. This will include the responsibility of posting
invoices and collections on Amsino’s billing and accounting system. Purchase orders will interface
with billing invoices receivables and payments. Amsino will verify credit worthiness and be
responsible for collections.

	 	 	 	 	 

	Agreed by Amsino

	 	/s/ Phllander Kelsey
	 	 
	 

	 	 	 	 
	 

	 	Phllander Kelsey	 	 

	 	 	 	 	 

	Agreed by Cytocore

	 	/s/ Robert McCullough Jr.
	 	 
	 

	 	 	 	 
	 

	 	Robert McCullough Jr.,	 	 

	11.	 	Each party can terminate the agreement on 90 day notice.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00173-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00173-of-00352.parquet"}]]